|
|
|
Volumn 16, Issue 2, 1995, Pages 283-288
|
|
Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: A feasibility trial
a
a
a
a
a
a
a
|
|
Author keywords
Autologous BMT; Immunotherapy; Interleukin 2
|
|
Indexed keywords
IMMUNOLOGIC AGENT;
INTERLEUKIN 2;
ADOLESCENT;
ADULT;
APHERESIS;
ARTICLE;
AUTOLOGOUS BONE MARROW TRANSPLANTATION;
CANCER SURVIVAL;
CELL CULTURE;
CELL TRANSPLANTATION;
CHILL;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DYSPNEA;
FEMALE;
FEVER;
HEALTH CARE COST;
HODGKIN DISEASE;
HOSPITALIZATION;
HUMAN;
HYPOTENSION;
IMMUNOTHERAPY;
INTRAVENOUS DRUG ADMINISTRATION;
LYMPHOKINE ACTIVATED KILLER CELL;
LYMPHOMA;
MALE;
NAUSEA;
NONHODGKIN LYMPHOMA;
PRIORITY JOURNAL;
RASH;
RELAPSE;
STEM CELL;
WEIGHT GAIN;
ADOLESCENT;
ADULT;
BONE MARROW TRANSPLANTATION;
FEMALE;
HUMANS;
IMMUNOTHERAPY, ADOPTIVE;
INTERLEUKIN-2;
KILLER CELLS, LYMPHOKINE-ACTIVATED;
LYMPHOMA;
MALE;
MIDDLE AGED;
TRANSPLANTATION, AUTOLOGOUS;
|
|
EID: 0029099188
PISSN: 02683369
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (78)
|
|
References (0)
|
